Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361815035> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4361815035 abstract "<div>AbstractPurpose:<p>To investigate the safety, clinical efficacy, virus pharmacokinetics, shedding, and immune response after administration of an oncolytic parvovirus (H-1PV, ParvOryx) to patients with metastatic pancreatic ductal adenocarcinoma (PDAC) refractory to first-line therapy.</p>Patients and Methods:<p>This is a noncontrolled, single-arm, open-label, dose-escalating, single-center clinical trial. Seven patients with PDAC and at least one liver metastasis were included. ParvOryx was administered intravenously on 4 consecutive days and as an intralesional injection, 6 to 13 days thereafter. Altogether, three escalating dose levels were investigated. In addition, gemcitabine treatment was initiated on day 28.</p>Results:<p>ParvOryx showed excellent tolerability with no dose-limiting toxicities. One patient had a confirmed partial response and one patient revealed an unconfirmed partial response according to RECIST criteria. Both patients showed remarkably long surivial of 326 and 555 days, respectively. Investigation of pharmacokinetics and virus shedding revealed dose dependency with no excretion of active virus particles in saliva or urine and very limited excretion in feces. H-1PV nucleic acids were detected in tumor samples of four patients. All patients showed T-cell responses to viral proteins. An interesting immunologic pattern developed in tumor tissues and in blood of both patients with partial response suggesting immune activation after administration of ParvOryx.</p>Conclusions:<p>The trial met all primary objectives, revealed no environmental risks, and indicated favorable immune modulation after administration of ParvOryx. It can be considered a good basis for further systematic clinical development alone or in combination with immunomodulatory compounds.</p></div>" @default.
- W4361815035 created "2023-04-05" @default.
- W4361815035 creator A5000827518 @default.
- W4361815035 creator A5001877436 @default.
- W4361815035 creator A5006080186 @default.
- W4361815035 creator A5012458272 @default.
- W4361815035 creator A5016751143 @default.
- W4361815035 creator A5020443258 @default.
- W4361815035 creator A5023646176 @default.
- W4361815035 creator A5037824137 @default.
- W4361815035 creator A5041359420 @default.
- W4361815035 creator A5048506787 @default.
- W4361815035 creator A5050832985 @default.
- W4361815035 creator A5058008889 @default.
- W4361815035 creator A5059234407 @default.
- W4361815035 creator A5059600151 @default.
- W4361815035 creator A5059944744 @default.
- W4361815035 creator A5062280027 @default.
- W4361815035 creator A5063203307 @default.
- W4361815035 creator A5067418623 @default.
- W4361815035 creator A5069413058 @default.
- W4361815035 creator A5084723610 @default.
- W4361815035 creator A5090324620 @default.
- W4361815035 creator A5090671577 @default.
- W4361815035 date "2023-03-31" @default.
- W4361815035 modified "2023-10-18" @default.
- W4361815035 title "Data from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma" @default.
- W4361815035 doi "https://doi.org/10.1158/1078-0432.c.6530628.v1" @default.
- W4361815035 hasPublicationYear "2023" @default.
- W4361815035 type Work @default.
- W4361815035 citedByCount "0" @default.
- W4361815035 crossrefType "posted-content" @default.
- W4361815035 hasAuthorship W4361815035A5000827518 @default.
- W4361815035 hasAuthorship W4361815035A5001877436 @default.
- W4361815035 hasAuthorship W4361815035A5006080186 @default.
- W4361815035 hasAuthorship W4361815035A5012458272 @default.
- W4361815035 hasAuthorship W4361815035A5016751143 @default.
- W4361815035 hasAuthorship W4361815035A5020443258 @default.
- W4361815035 hasAuthorship W4361815035A5023646176 @default.
- W4361815035 hasAuthorship W4361815035A5037824137 @default.
- W4361815035 hasAuthorship W4361815035A5041359420 @default.
- W4361815035 hasAuthorship W4361815035A5048506787 @default.
- W4361815035 hasAuthorship W4361815035A5050832985 @default.
- W4361815035 hasAuthorship W4361815035A5058008889 @default.
- W4361815035 hasAuthorship W4361815035A5059234407 @default.
- W4361815035 hasAuthorship W4361815035A5059600151 @default.
- W4361815035 hasAuthorship W4361815035A5059944744 @default.
- W4361815035 hasAuthorship W4361815035A5062280027 @default.
- W4361815035 hasAuthorship W4361815035A5063203307 @default.
- W4361815035 hasAuthorship W4361815035A5067418623 @default.
- W4361815035 hasAuthorship W4361815035A5069413058 @default.
- W4361815035 hasAuthorship W4361815035A5084723610 @default.
- W4361815035 hasAuthorship W4361815035A5090324620 @default.
- W4361815035 hasAuthorship W4361815035A5090671577 @default.
- W4361815035 hasBestOaLocation W43618150352 @default.
- W4361815035 hasConcept C112705442 @default.
- W4361815035 hasConcept C126322002 @default.
- W4361815035 hasConcept C197934379 @default.
- W4361815035 hasConcept C203014093 @default.
- W4361815035 hasConcept C2778375690 @default.
- W4361815035 hasConcept C2779984678 @default.
- W4361815035 hasConcept C31760486 @default.
- W4361815035 hasConcept C535046627 @default.
- W4361815035 hasConcept C71924100 @default.
- W4361815035 hasConcept C82210918 @default.
- W4361815035 hasConcept C8891405 @default.
- W4361815035 hasConcept C90924648 @default.
- W4361815035 hasConceptScore W4361815035C112705442 @default.
- W4361815035 hasConceptScore W4361815035C126322002 @default.
- W4361815035 hasConceptScore W4361815035C197934379 @default.
- W4361815035 hasConceptScore W4361815035C203014093 @default.
- W4361815035 hasConceptScore W4361815035C2778375690 @default.
- W4361815035 hasConceptScore W4361815035C2779984678 @default.
- W4361815035 hasConceptScore W4361815035C31760486 @default.
- W4361815035 hasConceptScore W4361815035C535046627 @default.
- W4361815035 hasConceptScore W4361815035C71924100 @default.
- W4361815035 hasConceptScore W4361815035C82210918 @default.
- W4361815035 hasConceptScore W4361815035C8891405 @default.
- W4361815035 hasConceptScore W4361815035C90924648 @default.
- W4361815035 hasLocation W43618150351 @default.
- W4361815035 hasLocation W43618150352 @default.
- W4361815035 hasOpenAccess W4361815035 @default.
- W4361815035 hasPrimaryLocation W43618150351 @default.
- W4361815035 hasRelatedWork W1985543168 @default.
- W4361815035 hasRelatedWork W2031700343 @default.
- W4361815035 hasRelatedWork W2115028228 @default.
- W4361815035 hasRelatedWork W2162350300 @default.
- W4361815035 hasRelatedWork W2981869943 @default.
- W4361815035 hasRelatedWork W3003574523 @default.
- W4361815035 hasRelatedWork W3030884457 @default.
- W4361815035 hasRelatedWork W3144862643 @default.
- W4361815035 hasRelatedWork W4240510682 @default.
- W4361815035 hasRelatedWork W4281624354 @default.
- W4361815035 isParatext "false" @default.
- W4361815035 isRetracted "false" @default.
- W4361815035 workType "article" @default.